OTCMKTS:ELLXF

Elixinol Global Competitors

$0.14
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.14
Now: $0.14
$0.15
50-Day Range
$0.14
MA: $0.16
$0.18
52-Week Range
$0.09
Now: $0.14
$0.33
Volume21,366 shs
Average Volume210,890 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Elixinol Global (OTCMKTS:ELLXF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying ELLXF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Elixinol Global, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Elixinol Global (OTCMKTS:ELLXF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Elixinol Global and Abacus Health Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Abacus Health Products0000N/A

Earnings & Valuation

This table compares Elixinol Global and Abacus Health Products' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Profitability

This table compares Elixinol Global and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Elixinol Global (OTCMKTS:ELLXF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares Elixinol Global and Acreage's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Elixinol Global and Acreage, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Acreage01202.67

Acreage has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, analysts clearly believe Acreage is more favorable than Elixinol Global.

Profitability

This table compares Elixinol Global and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
AcreageN/AN/AN/A

Summary

Acreage beats Elixinol Global on 2 of the 2 factors compared between the two stocks.

Elixinol Global (OTCMKTS:ELLXF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Elixinol Global and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Valuation & Earnings

This table compares Elixinol Global and Applied Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Elixinol Global and Applied Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Applied Biosciences0000N/A

Elixinol Global (OTCMKTS:ELLXF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Elixinol Global and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Earnings and Valuation

This table compares Elixinol Global and Ayr Strategies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Elixinol Global and Ayr Strategies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Ayr Strategies01602.86

Ayr Strategies has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts clearly believe Ayr Strategies is more favorable than Elixinol Global.

Summary

Ayr Strategies beats Elixinol Global on 2 of the 2 factors compared between the two stocks.

Elixinol Global (OTCMKTS:ELLXF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elixinol Global and Can B, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Can B0000N/A

Profitability

This table compares Elixinol Global and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
Can BN/AN/AN/A

Earnings and Valuation

This table compares Elixinol Global and Can B's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Elixinol Global (OTCMKTS:ELLXF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Profitability

This table compares Elixinol Global and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elixinol GlobalN/AN/AN/A
CansortiumN/AN/AN/A

Valuation and Earnings

This table compares Elixinol Global and Cansortium's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elixinol GlobalN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Elixinol Global and Cansortium, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elixinol Global0000N/A
Cansortium00103.00

Cansortium has a consensus target price of $1.20, suggesting a potential upside of 11.11%. Given Cansortium's higher possible upside, analysts plainly believe Cansortium is more favorable than Elixinol Global.

Summary

Cansortium beats Elixinol Global on 2 of the 2 factors compared between the two stocks.

Ad All Marijuana Stocks
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.

Elixinol Global Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00News Coverage
Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.38flat$0.00N/A0.00Increase in Short Interest
Gap Down
AYRSF
Ayr Strategies
1.4$21.26flat$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.50flat$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.08flat$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.01flat$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.09flat$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.07flat$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.23flat$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.75flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.3$11.98flat$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$13.09flat$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00flat$0.00N/A0.00Gap Up
EVIO logo
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00
Flower One logo
FLOOF
Flower One
0.4$0.22flat$0.00N/A0.00High Trading Volume
Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00Gap Down
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$27.15flat$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.61flat$0.00N/A0.00
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.87flat$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.02flat$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.19flat$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.28flat$0.00N/A0.00Gap Up
KNHBF
ICC International Cannabis
0.6$0.43flat$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.06flat$0.00N/A0.00
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.42flat$0.00N/A0.00Gap Down
KHTRF
Knight Therapeutics
1.2$4.18flat$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05flat$0.00N/A0.00News Coverage
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.37flat$0.00N/A0.00Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.28flat$0.00N/A0.00Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.52flat$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07flat$0.00N/A0.00Gap Up
MYHI
Mountain High Acquisitions
0.5$0.03flat$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.34flat$0.00N/A0.00Gap Up
Plus Products logo
PLPRF
Plus Products
1.1$0.50flat$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00
PCYN
Procyon
0.4$0.60flat$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Gap Up
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.03flat$0.00N/A0.00Increase in Short Interest
News Coverage
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40flat$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$10.14flat$0.00N/A0.00
The Flowr logo
FLWPF
The Flowr
1.5$0.23flat$0.00N/A0.00Gap Up
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.2$0.30flat$0.00N/A0.00Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.